Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG's Colorectal Cancer Treatment Stivarga Approved In Japan-DJ


Monday, 25 Mar 2013 04:26am EDT 

Dow Jones reported that Bayer AG said that Japan's Ministry of Health, Labor and Welfare has approved Stivarga tablets for the treatment of patients with unresectable, advanced/recurrent colorectal cancer. The approval is based on results from the pivotal Phase III CORRECT study that demonstrated an improvement in overall survival and progression-free survival compared to placebo in patients with metastatic CRC whose disease had progressed after approved standard therapies. Stivarga is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression - angiogenesis, oncogenesis and maintenance of the tumor microenvironment. 

Company Quote

144.94
7.77 +5.66%
18 Sep 2014